Citations

Clear

13603 citation(s) found for "_, _".

The need for an organoid manufacturing, preservation, and distribution center
Hermanson, David, Low, Walter C. , McKenna, David H. , Palecek, Sean P. , Temenoff, Johnna S. , Ogle, Brenda M. , Ogle, Brenda M , Atala, Anthony , Bischof, John C , Chen, Christopher S. , Fisher, John P. , Howe, Charles L. , Ma, Zhen

Mayo Clinic

Stem Cells Translational Medicine | June 19, 2025 | Volume: 14 | Issue: 7 | Pages: No page available

10.1093/stcltm/szaf031 | PMID 40627335 Get It

Abstract Organoids, which are tiny, lab-grown 3D structures that mimic some organizational and functional properties of human organs, are slowly transforming the face of systems and developmental biology, biomedical research, pharmaceutical testing, environmental toxin testing, and healthcare. Significant investments are essential for the mass production, preservation, and distribution of organoids, with the aim to accelerate innovation and progress across multiple fields—much like the investments made in cell and biologics manufacturing over the past 2 decades.
Clinical characteristics, treatment patterns and healthcare resource utilisation for portopulmonary hypertension patients in the USA: a real-world study
Small, Mark , Scott, Megan, Harley, Julia , Agron, Peter, Tsang, Yuen , Panjabi, Sumeet , DuBrock, Hilary, Harley, Julia , DuBrock, Hilary M.

Mayo Clinic

BMJ Open | June 19, 2025 | Volume: 15 | Issue: 6 | Pages: e089223

10.1136/bmjopen-2024-089223 | PMID 40537224 Get It

Objectives To investigate demographic, clinical characteristics, treatment patterns and healthcare resource utilisation (HCRU) among patients with portopulmonary hypertension (PoPH). Design Retrospective analysis of a real-world cross-sectional survey, the pulmonary arterial hypertension (PAH) Disease Specific Programme. Setting Secondary care settings in the USA. Participants Pulmonologists (n=22), cardiologists (n=17) and internists (n=7) who saw ≥2 patients with PAH/month provided data on 90 PoPH patients. Mean age of patients was 56.8 years, 51.1% were male, 76.7% were white/Caucasian. Primary and secondary outcome measures Demographic characteristics, initial presentation/diagnosis, disease trajectory, symptoms, comorbidities, treatment patterns and HCRU. Results The most common diagnostic tests were echocardiogram (62.2%), right heart catheterisation (56.7%) and electrocardiogram (48.9%). Dyspnea on exertion (64.4%), dyspnea following exertion (51.1%) and fatigue (48.9%) were the most common symptoms prior to PAH diagnosis as well as the most bothersome. Overall, 13.3% patients had mild disease before treatment vs 42.2% at time of survey. Most (60.0%) had stable disease (21.1% were improving and 18.8% were deteriorating at the time of the survey). Most common recent symptoms were dyspnea on exertion (51.1%), fatigue (37.8%) and dyspnea following exertion (32.2%). Patients had a mean of 1.8 comorbidities. In total, 80.0% of PoPH patients were receiving PAH-specific treatment; 41.7%, 22.2% and 12.5% received monotherapy, dual therapy and triple therapy, respectively. Patients had seen their physician 4.1 times in the past 12 months (3.5 visits specifically for PAH), while 31.1% had been hospitalised for PAH. Most (70.0%) patients were managed in a multidisciplinary team, and 8.9% of patients relied on a caregiver. Conclusions This study highlights the high symptomatic burden coupled with mostly moderate-to-severe disease status and a high hospitalisation rate despite the majority of PoPH patients being on therapy. Therefore, new treatment options in PoPH are in great need.
Quality of Life, Mood Disturbance, and Sexual Health in Implantable Cardioverter Defibrillators Recipients
Viancha, Rosa Amelia Herrera, Santos, Sueny Paloma Lima dos, Ortega, Orestes Román, Flórez-Flórez, Magda Lucía , Moore, Wendy C. , Tofthagen, Cindy , Herrera Viancha, Rosa Amelia , Tofthagen, Cindy S , Santos, Sueny Paloma Lima dos, Moore, Wendy C.

Mayo Clinic

Clinical Nursing Research | June 19, 2025 | Volume: 34 | Issue: 5 | Pages: 255-261

10.1177/10547738251347417 | PMID 40534457 Get It

Implantable Cardioverter Defibrillators (ICDs) are essential for managing life-threatening arrhythmias but can impact patients’ quality of life (QoL), mood, and sexual health. Although QoL may improve shortly after implantation, factors such as age, psychological state, and ICD shocks can influence long-term outcomes. Anxiety, depression, and fears around physical and sexual activity are common among ICD patients, yet the depth of these effects remains underexplored. This cross-sectional, correlational study examined associations between QoL, mood, and sexual health in 30 adult ICD patients (ages 27–83) within 3 years postimplantation, recruited from a Southeastern U.S. academic medical center. Participants completed the SF-36, Profile of Mood States, and Multidimensional Sexuality Questionnaire. Spearman’s correlations indicated that lower QoL was significantly associated with higher mood disturbance (rho = −0.645, p < .001) and lower sexual health (rho = 0.535, p = .005), though no significant link was found between mood disturbance and sexual health (rho = −0.279, p = .168). Multiple linear regression confirmed that QoL was influenced by both mood and sexual health. Post-hoc power analysis using EpiData verified that the sample size ( n = 30) provided 90% power with a 5% error rate. These findings underscore the importance of addressing emotional and sexual well-being in ICD patient care. Targeted interventions could improve outcomes, but further research with larger samples is needed to deepen understanding of these relationships.
Assessment and classification of sex cord‐stromal tumours of the testis: recommendations from the testicular sex cord‐stromal tumour ( TESST ) group, an Expert Panel of the Genitourinary Pathology Society
Acosta, Andrés , Compérat, Éva , Cornejo, Kristine M. , Gupta, Sounak , Cheville, John C. , Idrees, Muhammad T. , Raspollini, Maria Rosaria , Reyes‐Múgica, Miguel , Tickoo, Satish K. , Ulbright, Thomas M. , Sholl, Lynette M. , Gonzalez‐Peramato, Pilar, Acosta, Andrés M , Comperat, Eva , Raspollini, Maria Rosaria , Tsuzuki, Toyonori , Williamson, Sean R , Siegmund, Stephanie , Sholl, Lynette , Berney, Daniel M , Reyes-Mugica, Miguel , Colecchia, Maurizio , Gill, Anthony J. , Kao, Chia‐Sui , Maclean, Fiona M. , Matoso, Andres , Michalova, Kvetoslava , Tsuzuki, Toyonori , Williamson, Sean R. , Berney, Daniel M.

Mayo Clinic

Histopathology | June 18, 2025 | Volume: 87 | Issue: 5 | Pages: 660-676

10.1111/his.15482 | PMID 40528632 Get It

Aims Testicular sex cord‐stromal tumours (TSCSTs) are relatively rare, accounting for ~5% of all testicular neoplasms. They were historically classified into Leydig cell tumour, Sertoli cell tumour, granulosa cell tumour, and unclassified sex cord‐stromal tumour. More recently, classification was expanded to incorporate additional histologic types, including some associated with inherited cancer predisposition syndromes. However, the classification of TSCSTs still relies entirely on morphology, with some tumour types being defined based on their resemblance to ovarian counterparts. In recent years, molecular studies have identified drivers and genomic alterations associated with aggressive behaviour and progression; however, these findings have not yet impacted classification and management. Methods and results Under sponsorship of the International Society of Urological Pathology (ISUP) and the Genitourinary Pathology Society (GUPS), a group of genitourinary pathologists was assembled in 2023 with the aim of assessing how to use these new data to improve the classification and management of TSCSTs. Conclusions This paper summarizes the recommendations derived from the consensus activities and the first meeting of the te sticular s ex cord‐ s tromal t umour (TESST) group (held at Johns Hopkins Hospital, Baltimore, USA, 3/23/2024).
Posterior Graft Laryngotracheal Reconstruction for Bilateral Vocal Cord Paralysis in a Resource-Limited Setting: Building a Replicable Airway Reconstruction Program in Eldoret, Kenya
Isaac, André , Menach, Owen , Rotich, Gerald, Callaghan, Amy, Isaac, Daniela Migliarese , Wiedermann, Josh, Holinski, Paula , Anton, Natalie , Propst, Evan J. , Ngoitsi, Henry, Isaac, Daniela M , Rotich, Gerald

Mayo Clinic

Journal of Otolaryngology - Head & Neck Surgery | June 17, 2025 | Volume: 54 | Issue: No issue available | Pages: No page available

10.1177/19160216251345468 | PMID 40528278 Get It

Importance Bilateral vocal cord paralysis is a challenging problem to manage in adults, and a known complication of thyroid surgery which is more common in resource-limited settings. Posterior graft laryngotracheal reconstruction is a management option that has not been studied in this population or setting. Objective To report the surgical outcomes of posterior graft laryngotracheal reconstruction for bilateral vocal cord paralysis in a resource-limited setting, and to evaluate the efficacy of a hybrid system for teaching this technique in Kenya. Design Retrospective cohort study. Setting Tertiary public referral hospital, Eldoret, Kenya Participants Adults >18 years with tracheostomy dependence secondary to bilateral vocal cord paralysis after thyroid surgery or other iatrogenesis. The hybrid training program included Kenyan surgeons and surgical trainees. Intervention or Exposures Posterior graft laryngotracheal reconstruction and hybrid training system included didactic lectures, simulation-based training, case discussion and planning, and live cases. Main Outcomes Measures One-year airway outcomes measured by achievement of tracheostomy decannulation, and self-reported surgeon knowledge and skill acquisition. Results Ten patients met criteria and were included in the analysis, with mean age 42 years (range 30-62 years) and had been tracheostomy dependent for an average of 6 years (range 1-12 years). Seven (70%) had open reconstruction, and 3 (30%) had endoscopic reconstruction. All were decannulated and remained tracheostomy-free at 1 year. Three surgeons and 7 trainees participated in the hybrid teaching methods. All reported increased comfort in laryngotracheal reconstruction, with all 3 surgeons reporting comfort performing the surgeries independently. Conclusion Posterior graft laryngotracheal reconstruction shows promise as a potential method of treating bilateral vocal cord paralysis and achieving decannulation in a resource-limited setting. Relevance The methods reported in this study lend themselves to replication and expansion to other similar settings. The authors plan to replicate this work in other centers in East Africa.
Contemporary TAVR for Patients With Bicuspid Aortic Valve: Importance of Specific Bicuspid Phenotypes, Raphe, Calcification, and a Lifetime Management Intention
Michelena, Héctor I. , Patel, Dhairya , Makkar, Raj, Jilaihawi, Hasan , Michelena, Hector I , Makkar, Raj

Mayo Clinic

Circulation: Cardiovascular Interventions | June 17, 2025 | Volume: 18 | Issue: 6 | Pages: No page available

10.1161/circinterventions.125.015442 | PMID 40526784 Get It

Cardiac Computed Tomography for Prosthetic Heart Valve Assessment. An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the European Soci
Budde, Ricardo P.J. , Faure, M. , Cremer, Paul , Feuchtner, Gudrun , Gonzales, Holly M, Kiefer, Todd L., Leipsic, Jonathon , Nieman, Koen , Williamson, Eric E. , Ballmoos, Moritz C. Wyler von , Salgado, Rodrigo , Faure, Marguerite E , Abbara, Suhny , Alkadhi, Hatem , Cremer, Paul C , Feuchtner, Gudrun M , Gonzales, Holly M , Leipsic, Jonathan , Nieman, Koen , Revels, Jonathan W , Wang, Dee Dee , Williamson, Eric , Salgado, Rodrigo , Budde, Ricardo Peter Jurgen , Revels, Jonathan , Wang, Dee Dee , Zwischenberger, Brittany A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | June 17, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1148/ryct.250231 | PMID 40526484 Get It

Prosthetic heart valve (PHV) dysfunction is increasingly seen due to the increase in the number of PHV that are being implanted worldwide. Cardiac CT imaging has emerged as a valuable tool to assess PHVs and determine the cause of dysfunction. This consensus document first summarizes the available techniques for PHV assessment. Then the use of CT in PHV (dys)function assessment is discussed in detail including consensus statements for correct indications and patient selection for CT assessment of PHVs, image acquisition, reconstruction and measurement protocols and how to interpret and report the CT findings for specific types of PHV dysfunction. This article was published in Journal of Cardiovascular Computed Tomography, Budde RPJ et al, Cardiac computed tomography for prosthetic heart valve assessment: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the European Society of Cardiovascular Radiology (ESCR), the North American Society for Cardiovascular Imaging (NASCI), the Radiological Society of North America (RSNA), the Society for Cardiovascular Angiography & Interventions (SCAI), and the Society of Thoracic Surgeons (STS). The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation may be used when referencing this document. © 2025 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. on behalf of the Society of Cardiovascular Computed Tomography. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). Keywords: Computed Tomography, Valve, Cardiac, Imaging, Dysfunction, Prosthetic
Recognizing Exocrine Pancreatic Insufficiency in Patients with Diabetes: A Case Study
Kusztos, Victoria , Pogorelova, M. A. , Pogorelova, Mariya , Pogorelova, Mariya

Mayo Clinic

American Journal of Case Reports | June 17, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.948283 | PMID 40671282 Get It

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management
Shimony, Shai , Luskin, Marlise R. , Gangat, Naseema , LeBoeuf, Nicole R, Feraco, Angela M. , Luskin, Marlise R , Shimony, Shai , LeBoeuf, Nicole R. , Lane, Andrew A.

Mayo Clinic

American Journal of Hematology | June 17, 2025 | Volume: 100 | Issue: 8 | Pages: 1408-1422

10.1002/ajh.27737 | PMID 40525728 Get It

ABSTRACTOverviewBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic neoplasm that involves multiple organs, including the skin, bone marrow and blood, lymph nodes, and central nervous system. Violaceous tumors or plaques appearing in sun‐exposed areas are characteristic and present in most patients. The disease typically affects adult men aged 60–70 years, although children and younger adults may also be affected.DiagnosisDiagnosis is based on biopsy of an involved site and is typically based on the identification of blastoid cells displaying the classical immunophenotypes CD123, CD4, and CD56 in addition to specific pDC markers.PrognosisThe median overall survival is 18–24 months. Potential risk factors for shortened survival include older age, overt bone marrow involvement, and genetic abnormalities.Therapy and ManagementEither chemotherapy‐based regimens or tagraxofusp, a CD123‐directed interleukin 3 conjugated with diphtheria toxin, may be used for upfront therapy. Eligible patients are recommended to be consolidated with hematopoietic allogeneic stem cell transplantation. Assessment and treatment of the central nervous system is mandatory, and careful monitoring of skin disease in conjunction with dermatology is essential.
Patients’ Concerns About Receiving Preemptive Pharmacogenomic Testing: Results from a Large, Longitudinal Survey of RIGHT Study Participants
Pacyna, Joel E. , Bielinski, Suzette J. , Olson, Janet E., Sharp, Richard R. , Sharp, Richard R , Bielinski, Suzette

Mayo Clinic

Journal of Personalized Medicine | June 17, 2025 | Volume: 15 | Issue: 6 | Pages: 258

10.3390/jpm15060258 | PMID 40559120 Get It

Background: As more healthcare institutions consider providing preemptive pharmacogenomic (PGx) testing to greater numbers of their patients, it will be important to consider the potential concerns patients may have about the generation of preemptive PGx information. To date, few studies have examined the nature and incidence of patient concerns about preemptive PGx testing. Methods: We conducted a longitudinal survey study of 5000 patients receiving preemptive PGx testing in the Mayo Clinic RIGHT study. We assessed patient concerns regarding issues of data confidentiality, cost implications, comprehension of results, and potential disruption of pre-existing medication regimens. Participants were surveyed before and after they received PGx results from the RIGHT study. Results: We achieved 92.8% and 74.4% response rates on the pre- and post-results surveys, respectively. Participants had low levels of concern about PGx testing overall. However, 25.5% of participants were “quite/extremely concerned” about insurance implications, and 30.1% were “quite/extremely” concerned about increased out-of-pocket costs for prescription medications that might result from PGx testing. These same concerns were significantly reduced on the post-results survey. Patients who initially expressed concerns regarding their ability to understand PGx results were more likely to report having difficulty understanding results on the post-results survey. Conclusions: Our findings suggest that as healthcare institutions look to increase preemptive PGx screening, attention should be given to potential concerns patients may have around such testing. Educational interventions aimed at supporting patient understanding of PGx results and addressing potential concerns will be important elements of a successful PGx program.